← All trials
NCT07230119
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 8, 2026
- Primary completion
- May 29, 2027
- Completion date
- Jun 26, 2027
- First posted
- Nov 17, 2025
- Last posted
- Nov 19, 2025
- Enrollment
- 620
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing QL Biopharmaceutical Co.,LtdLead sponsor
- Peking UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.